Incyte today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback